Amylyx officer Frates proposes $1.18M share sale

The proposed shares are to come from stock-option exercises over the next three months under a plan adopted April 10, 2026.

Available on EDGAR 11/09/2026 - 04:36 PM EST Accepted by SEC EDGAR 11/09/2026 - 04:36 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Amylyx Pharmaceuticals, Inc. (AMLX) reports that Officer James M. Frates gave notice of a proposed sale of 40,000 common shares, with an aggregate market value of $1,180,000 and an approximate sale date of November 9, 2026. The shares were and will be received through stock-option exercises over the next three months; the notice identifies a Rule 10b5-1 plan adopted April 10, 2026.

It also lists a September 10, 2026 sale by James M. Frates of 10,810 common shares for gross proceeds of $349,820.67.

Key Figures

Common shares proposed for sale: 40,000 shares Aggregate market value: $1,180,000 Common shares outstanding: 128,562,904 shares +3 more

6 metrics

Common shares proposed for sale 40,000 shares Approximate sale date: November 9, 2026

Aggregate market value $1,180,000 Proposed sale of common shares

Common shares outstanding 128,562,904 shares Share count listed in the notice

Common shares sold 10,810 shares Sale on September 10, 2026

Gross proceeds $349,820.67 Sale on September 10, 2026

Rule 10b5-1 plan adoption date April 10, 2026 Plan identified for the proposed sale

Key Terms

Rule 10b5-1, Exercise of Stock Options, Aggregate Market Value

3 terms

Rule 10b5-1 regulatory

"If Relying on Rule 10b5-1"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

Exercise of Stock Options financial

"Nature of Acquisition Transaction: Exercise of Stock Options"

Aggregate Market Value financial

"Aggregate Market Value"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many AMLX shares does James M. Frates plan to sell?

James M. Frates, an officer of Amylyx Pharmaceuticals, Inc., gave notice to sell 40,000 common shares, with an aggregate market value of $1,180,000 and an approximate sale date of November 9, 2026. The shares are to be received through stock-option exercises over the next three months under a Rule 10b5-1 plan adopted April 10, 2026.

What AMLX shares did James M. Frates sell in the prior three months?

The notice lists a sale of 10,810 common shares on September 10, 2026, with gross proceeds of $349,820.67.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001235598
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	AMYLYX PHARMACEUTICALS, INC.
SEC File Number	001-41199
Address of Issuer	55 Cambridge Parkway, Suite 6W CAMBRIDGE MASSACHUSETTS 02142
Phone	(617)-682-0917
Name of Person for Whose Account the Securities are To Be Sold	JAMES M FRATES
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	40000	1180000.00	128562904	11/09/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	11/09/2026	Exercise of Stock Options	Issuer			40000	11/09/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
JAMES M FRATES 55 Cambridge Parkway, Suite 6W CAMBRIDGE MA 02142	Common	09/10/2026	10810	349820.67

144: Remarks and Signature

Remarks	The securities to be sold were and will be received upon the exercise of stock options over the next three months. The dates of acquisition and payment were and will be the dates of exercise/sale.
Date of Notice	11/09/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	04/10/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	James M Frates
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)